content: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of Report (Date of earliest event reported)   JUNE 30, 1995       ENZON,
  
  INC.
  
                     (Exact  name  of  registrant  as  specified in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  ITEM 5.  OTHER EVENTS
  
       Enzon,  Inc.  ("Enzon" or the "Company") and Schering  Corporation,  a
  subsidiary  of  Schering-Plough   Corporation  ("Schering"),  have  further
  amended  (the  "Revised  Agreement")  their   November   1990  license  and
  development  agreement for PEG-INTRON A (the "Original Agreement").   Under
  the Revised Agreement,  Schering  will  obtain Enzon's proprietary know-how
  for PEG-Intron A and acquire manufacturing  rights previously held by Enzon
  with respect to manufacturing PEG-Intron A.   Enzon has an option to become
  Schering's exclusive manufacturer of PEG-INTRON  A  for  the  U.S.  market.
  Schering will retain exclusive worldwide marketing rights for PEG-INTRON  A
  and continue to be responsible for conducting clinical studies and securing
  regulatory  approval.   Enzon is entitled to receive the milestone payments
  and royalties provided by  the  Original  Agreement.   In  addition to such
  milestone payments, Schering paid to Enzon a $2,000,000 license fee with an
  additional  $1,000,000  to  be  paid  upon  completion  of  the  technology
  transfer.   Last  quarter  Enzon  delivered  to  Schering two PEG-INTRON  A
  formulations  having improved performance characteristics  for  anticipated
  clinical trials.
  
       Concurrently  with executing the Revised Agreement, Schering purchased
  847,849 shares (the  "Shares") of Enzon's common stock, $.01 par value, for
  aggregate  consideration   of   $2,000,000.    Schering   received   demand
  registration  rights exercisable no sooner than January 1996 and piggy-back
  registration rights with respect to the Shares.
  
  
                              SIGNATURES
  
  
       Pursuant to  the  requirements of the Securities Exchange Act of 1934,
  
  the Registrant has duly  caused  this  report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  Dated:  July 20, 1995
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /S/  JOHN  A.  CARUSO      John A.
  Caruso
                                           Vice President,Business Development
                                           and General Counsel
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3111}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "95555012"}, "business-address": {"street1": "40 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of Report (Date of earliest event reported)   JUNE 30, 1995       ENZON,
  
  INC.
  
                     (Exact  name  of  registrant  as  specified in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  
  ITEM 5.  OTHER EVENTS
  
       Enzon,  Inc.  ("Enzon" or the "Company") and Schering  Corporation,  a
  subsidiary  of  Schering-Plough   Corporation  ("Schering"),  have  further
  amended  (the  "Revised  Agreement")  their   November   1990  license  and
  development  agreement for PEG-INTRON A (the "Original Agreement").   Under
  the Revised Agreement,  Schering  will  obtain Enzon's proprietary know-how
  for PEG-Intron A and acquire manufacturing  rights previously held by Enzon
  with respect to manufacturing PEG-Intron A.   Enzon has an option to become
  Schering's exclusive manufacturer of PEG-INTRON  A  for  the  U.S.  market.
  Schering will retain exclusive worldwide marketing rights for PEG-INTRON  A
  and continue to be responsible for conducting clinical studies and securing
  regulatory  approval.   Enzon is entitled to receive the milestone payments
  and royalties provided by  the  Original  Agreement.   In  addition to such
  milestone payments, Schering paid to Enzon a $2,000,000 license fee with an
  additional  $1,000,000  to  be  paid  upon  completion  of  the  technology
  transfer.   Last  quarter  Enzon  delivered  to  Schering two PEG-INTRON  A
  formulations  having improved performance characteristics  for  anticipated
  clinical trials.
  
       Concurrently  with executing the Revised Agreement, Schering purchased
  847,849 shares (the  "Shares") of Enzon's common stock, $.01 par value, for
  aggregate  consideration   of   $2,000,000.    Schering   received   demand
  registration  rights exercisable no sooner than January 1996 and piggy-back
  registration rights with respect to the Shares.
  
                              SIGNATURES
  
       Pursuant to  the  requirements of the Securities Exchange Act of 1934,
  
  the Registrant has duly  caused  this  report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  July 20, 1995
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /S/  JOHN  A.  CARUSO      John A.
  Caruso
                                           Vice President,Business Development
                                           and General Counsel